h-hydrogen

The use of different mathematical models to support medical decisions is accompanied by increasing uncertainties when they are applied in practice. Using prostate cancer (PCa) risk models as an example, we recommend requirements for model development and draw attention to possible pitfalls so as to avoid the uncritical use of these models.

We conducted MEDLINE searches for applications of multivariate models supporting the prediction of PCa risk. We critically reviewed the methodological aspects of model development and the biological and analytical variability of the parameters used for model development. In addition, we reviewed the role of prostate biopsy as the gold standard for confirming diagnoses. In addition, we analyzed different methods of model evaluation with respect to their application to different populations. When using models in clinical practice, one must validate the results with a population from the application field. Typical model characteristics (such as discrimination performance and calibration) and methods for assessing the risk of a decision should be used when evaluating a model's output. The choice of a model should be based on these results and on the practicality of its use.

To avoid possible errors in applying prediction models (the risk of PCa, for example) requires examining the possible pitfalls of the underlying mathematical models in the context of the individual case. The main tools for this purpose are discrimination, calibration, and decision curve analysis.

Human epididymis protein 4 (HE4), a precursor of human epididymis protein, has been proposed as a tumor marker for ovarian cancer. We evaluated HE4 in comparison with cancer antigen 125 (CA 125) in healthy individuals and in patients with benign and malignant diseases.

CA 125 and HE4 serum concentrations were determined in 101 healthy individuals, 535 patients with benign pathologies (292 with benign gynecologic diseases) and 423 patients with malignant diseases (127 with ovarian cancers). CA 125 and HE4 cutoffs were 35 kU/L and 140 pmol/L, respectively.

HE4 and CA 125 results were abnormal in 1.1% and 9.9% of healthy individuals and in 12.3% and 37% of patients with benign diseases, respectively. Renal failure was the most common cause of increased HE4 in patients with benign disease, who had significantly higher HE4 concentrations (P = 0.001) than patients with other benign diseases. HE4 showed a higher specificity than CA 125 in patients with benign gynecologic diseases, with abnormal concentrations in 1.3% and 33.2% of the patients, respectively. HE-4 concentrations were abnormal primarily in gynecologic cancer and lung cancer. By contrast, CA 125 was increased in many different nonovarian malignancies, including nonepithelial tumors. A significantly higher area under the ROC curve was obtained with HE4 than with CA 125 for differentiating benign from malignant diseases (0.755 vs 0.643) and in the differential diagnosis of gynecologic diseases (0.874 vs 0.722).

HE4 has significantly higher diagnostic specificity than CA 125, and the combination of CA 125 and HE4 improved the detection of ovarian cancer in all stages and histological types.

Prostate cancer is the most commonly diagnosed cancer among men in North America and is a leading cause of death. Standard treatments include androgen deprivation therapy, which leads to improved clinical outcomes. However, over time, most tumors become androgen independent and no longer respond to hormonal therapies. Several mechanisms have been implicated in the progression of prostate cancer to androgen independence.

Most tumors that have become androgen independent still rely on androgen receptor (AR) signaling. Mechanisms that enhance AR signaling in androgen-depleted conditions include: AR gene amplification, AR mutations, changes in the balance of AR cofactors, increases in steroidogenic precursors, and activation via "outlaw" pathways. Along with AR signaling, various other AR-independent "bypass" pathways have been shown to operate aberrantly during androgen independence. Changes in the epigenetic signatures and microRNA concentrations have also been implicated in the development of androgen-independent prostate cancer.

Understanding of the molecular mechanisms that lead to the development of androgen-independent prostate cancer will allow for improved therapeutic strategies that target key pathways and molecules that are essential for these cells to survive.

Circulating tumor cell (CTC) analysis is a promising new diagnostic field for estimating the risk for metastatic relapse and metastatic progression in patients with cancer.

Different analytical systems for CTC isolation and detection have been developed as immunocytochemical and molecular assays, most including separation steps by size or biological characteristics, such as expression of epithelial- or cancer-specific markers. Recent technical advancements in CTC detection and characterization include methods based on multiplex reverse-transcription quantitative PCR and approaches based on imaging and microfilter and microchip devices. New areas of research are directed toward developing novel assays for CTC molecular characterization. QC is an important issue for CTC analysis, and standardization of micrometastatic cell detection and characterization methodologies is important for the incorporation of CTCs into prospective clinical trials to test their clinical utility. The molecular characterization of CTCs can provide important information on the molecular and biological nature of these cells, such as the status of hormone receptors and epidermal and other growth factor receptor family members, and indications of stem-cell characteristics. This information is important for the identification of therapeutic targets and resistance mechanisms in CTCs as well as for the stratification of patients and real-time monitoring of systemic therapies.

CTC analysis can be used as a liquid biopsy approach for prognostic and predictive purposes in breast and other cancers. In this review we focus on state-of-the-art technology platforms for CTC isolation, imaging, and detection; QC of CTC analysis; and ongoing challenges for the molecular characterization of CTCs.

Background: Cancer has downright effects on gene expression, including a cell’s glycosylation machinery. Thus, tumors show glycoproteins that conduct oligosaccharides with structures that are markedly sundry from the after all is said protein produced by a general room. A pick protein can deliver assorted glycosylation sites that greatly detail the signals they forge compared with their protein backbones.

Content: In this article, we scan clinical tests that end carbohydrate modifications for diagnosing and treating cancer. We up to date the biological suitableness of glycosylation to contagion making by highlighting the part these structures entertainment in adhesion, signaling, and metastasis and then talk to drift methodological approaches to biomarker finding that capitalize on selectively capturing tumor-associated glycoforms to adorn and sort out disease-related seeker analytes. Finally, we examine emerging technologies—multiple revenge monitoring and lectin-antibody arrays—as capacity tools for biomarker validation studies in running down of clinically utilitarian tests.

Summary: The unborn of carbohydrate-based biomarker studies has arrived. At all stages, from ascertaining into done with verification and deployment into clinics, glycosylation should be considered a cardinal readout or a way of increasing the susceptivity and specificity of protein-based analyses.

Background: Hepatocellular carcinoma (HCC) is a well-known and lickety-split fatal cancer. Up to date diagnostic methods for HCC contain insignificant awareness and specificity, are invasive, and pinch chance for complications. Newer markers are needed to subdue these problems and acknowledge diagnosis of HCC at an earlier acting. In representation of prominent associations middleman glycosylation changes and liver disease, we focused on the serum glycoprotein hemopexin and the limited characteristics of this liver-synthesized glycoprotein.

Methods: We feigned 49 healthy volunteers and 81 patients divided into the categories of fibrosis, cirrhosis, and HCC with cirrhosis. Hemopexin was purified from examine participants’ serum by use of heme agarose beads. The hemopexin N-glycan make a killing was resolute by use of the DNA sequencer–assisted fluorophore-assisted carbohydrate electrophoresis standard operating procedure.

Results: We found that branching -1,3-fucosylated multiantennary glycans on hemopexin were increased in the HCC platoon compared with the cirrhosis without HCC, fibrosis, and healthy volunteer groups, whereas nonmodified biantennary glycans decreased progressively across groups from fibrosis to the cirrhosis and HCC groups. Summarization of this info in a new marker, soi-disant the hemopexin glycan marker, enabled celebrity of patients with HCC and cirrhosis from salubrious volunteers and patients with fibrosis or cirrhosis with a sensitiveness and specificity of 79% and 93%, respectively.

Conclusions: This study demonstrated hemopexin to be a likeness protein for studying liver-specific N-glycosylation. The hemopexin glycan marker could be a valuable complementary check to -fetoprotein measurements for detection of HCC in patients with cirrhosis. Additional over of its utility for diagnosis and follow-up is recommended.

Background: Updated National Academy of Clinical Biochemistry Laboratory Pharmaceutical Usage Guidelines for the use of tumor markers in the clinic have in the offing been developed.

Methods: Published reports applicable to use of tumor markers for 4 cancer sites—liver, bladder, cervical, and gastric—were critically reviewed.

Results: -Fetoprotein (AFP) may be habituated to in conjunction with abdominal ultrasound for early detection of hepatocellular carcinoma (HCC) in patients with lingering hepatitis or cirrhosis associated with hepatitis B or C virus infection. AFP concentrations >200 µg/L in cirrhotic patients with regular hypervascular lesions >2 cm in bigness are regular with HCC. After a diagnosis of HCC, posttreatment monitoring with AFP is recommended as an adjunct to imaging, principally in the scantiness of measurable illness.

Although several urine markers organize been proposed for bladder cancer, not any at bonus can make good on designated cystoscopy and cytology in the managing of patients with this malignancy. Some may, however, be toughened as complementary adjuncts to unambiguous more actual use of clinical procedures.

Although carcinoembryonic antigen and CA 19-9 sire been proposed for use gastric cancer and squamous chamber carcinoma antigen for use in cervical cancer, not one of these markers can currently be recommended for habitual clinical use.

Conclusions: Implementation of these recommendations should embolden optimal use of tumor markers for patients with liver, bladder, cervical, or gastric cancers.